- Zacks•43 minutes ago
Pfizer (PFE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- Market Realist•48 minutes ago
On June 6, Pfizer and Merck announced positive results from a Phase 2 study testing Avelumab as a therapy for previously treated Merkel cell carcinoma.
- optionMONSTER•2 hours ago
Pfizer is drawing upside option activity ahead of quarterly results next week. OptionMonster's monitoring program shows that 10,000 January 33 calls were purchased for $0.79 yesterday. Volume surpassed ...
Pfizer Inc. (PFE)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||32.26 x 11300|
|Ask||32.27 x 3900|
|Day's Range||32.04 - 32.56|
|52wk Range||28.25 - 37.39|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||28.62|
|Avg Vol (3m)||19,193,012|
|Dividend & Yield||1.20 (3.70%)|